166 related articles for article (PubMed ID: 1956253)
1. [More drugs against HIV/AIDS will soon be available as a review over the drug development shows].
Oberg B
Lakartidningen; 1991 Nov; 88(48):4139-42. PubMed ID: 1956253
[No Abstract] [Full Text] [Related]
2. Antiretroviral drug resistance in non-subtype B HIV-1, HIV-2 and SIV.
Parkin NT; Schapiro JM
Antivir Ther; 2004 Feb; 9(1):3-12. PubMed ID: 15040531
[TBL] [Abstract][Full Text] [Related]
3. What we know about anti-HIV drugs.
Treat Rev; 1995 May; (no 18):3-4. PubMed ID: 11362592
[TBL] [Abstract][Full Text] [Related]
4. Let there be drugs.
Gilden D
GMHC Treat Issues; 1996 Feb; 10(2):1, 13-6. PubMed ID: 11363380
[TBL] [Abstract][Full Text] [Related]
5. Update on antiretroviral therapy of HIV infection.
Vella S
J Biol Regul Homeost Agents; 1994; 8(3):71-6. PubMed ID: 7754791
[TBL] [Abstract][Full Text] [Related]
6. Human immunodeficiency virus type 1 protease inhibitors.
McDonald CK; Kuritzkes DR
Arch Intern Med; 1997 May; 157(9):951-9. PubMed ID: 9140265
[TBL] [Abstract][Full Text] [Related]
7. [HIV protease inhibitors (new possibilities in the treatment of HIV infection and AIDS)].
Bálint GS
Orv Hetil; 1998 Jun; 139(24):1471-4. PubMed ID: 9658865
[TBL] [Abstract][Full Text] [Related]
8. [New formulation--fewer tablets--optimal effect].
Krankenpfl J; 2005; 43(7-10):249. PubMed ID: 16515318
[No Abstract] [Full Text] [Related]
9. Antiretroviral drug treatment for HIV/AIDS.
Goldschmidt RH; Moy A
Am Fam Physician; 1996 Aug; 54(2):574-80, 587-8. PubMed ID: 8701838
[TBL] [Abstract][Full Text] [Related]
10. Therapy other than reverse transcriptase inhibitors for HIV infection.
Kaplan JC; Hirsch MS
Clin Lab Med; 1994 Jun; 14(2):367-91. PubMed ID: 7523020
[TBL] [Abstract][Full Text] [Related]
11. Top AIDS researchers' strategy for antiretroviral treatment.
AIDS Alert; 1996 Sep; 11(9):97-100. PubMed ID: 11363728
[TBL] [Abstract][Full Text] [Related]
12. HIV-1 drug resistance. Molecular pathogenesis and laboratory monitoring.
D'Aquila RT
Clin Lab Med; 1994 Jun; 14(2):393-422. PubMed ID: 7523021
[TBL] [Abstract][Full Text] [Related]
13. HIV genetic diversity: any implications for drug resistance?
Jülg B; Goebel FD
Infection; 2005 Aug; 33(4):299-301. PubMed ID: 16091906
[TBL] [Abstract][Full Text] [Related]
14. The history of HIV-1 testing.
Bean P
Am Clin Lab; 2000 May; 19(4):4. PubMed ID: 10947317
[No Abstract] [Full Text] [Related]
15. Protease inhibitors: implications for HIV research and treatment.
Churchill SA
J Int Assoc Physicians AIDS Care; 1996 Jan; 2(1):13-8. PubMed ID: 11363325
[TBL] [Abstract][Full Text] [Related]
16. [Variants of HIV-2 and HIV-2 and approaches for chemotherapy of HIV infection].
Rübsamen-Waigmann H
Offentl Gesundheitswes; 1989; 51(8-9):562-6. PubMed ID: 2531353
[TBL] [Abstract][Full Text] [Related]
17. A synthetic HIV-1 protease inhibitor with antiviral activity arrests HIV-like particle maturation.
Dis Markers; 1990; 8(3):162-3. PubMed ID: 2125537
[No Abstract] [Full Text] [Related]
18. Cerebrospinal fluid human immunodeficiency virus type 1 RNA levels are elevated in neurocognitively impaired individuals with acquired immunodeficiency syndrome. HIV Neurobehavioral Research Center Group.
Ellis RJ; Hsia K; Spector SA; Nelson JA; Heaton RK; Wallace MR; Abramson I; Atkinson JH; Grant I; McCutchan JA
Ann Neurol; 1997 Nov; 42(5):679-88. PubMed ID: 9392566
[TBL] [Abstract][Full Text] [Related]
19. [New ammunition in the battle against AIDS].
Agosto M
Sidahora; 1997; ():25-6. PubMed ID: 11364803
[TBL] [Abstract][Full Text] [Related]
20. [New treatments for HIV].
Garcia E
Sidahora; 1996; ():48-50. PubMed ID: 11363630
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
